About PackGene

Packgene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
PackGene offers 8,000m² state-of-the-art GMP facilities in compliance with the FDA, NMPA, and EMA regulatory requirements with the first 4,000L GMP AAV production capacity in Asia. We have successfully delivered over 10,000 batches of research-grade AAV packaging services for hundreds of big pharma, biotech and research institutions from the United States, Europe, Asia Pacific, and China. We dedicate ourselves to the new serotype AAV vectors development and high-yield AAV production technology to accelerate your gene therapy programs. PackGene continuously strives to improve the quality, yield, efficacy, and safety of plasmid DNA and AAV vector to make gene therapy affordable for patients.